Advertisement
Table 1 Selected patient, tumor and treatment characteristics
From: Parotid gland shrinkage during IMRT predicts the time to Xerostomia resolution
| Characteristic | Stratification | # pts | % |
|---|---|---|---|
| Sex | Male | 77 | 90.6 |
| Female | 8 | 9.4 | |
| Primary tumor site | Tonsil | 37 | 43.5 |
| Base of tongue | 46 | 54.1 | |
| Pharyngeal wall | 2 | 2.4 | |
| AJCC stage | I | 2 | 2.4 |
| II | 7 | 8.2 | |
| III | 8 | 9.4 | |
| IV | 68 | 80.0 | |
| Smoking at diagnosis | No | 67 | 78.8 |
| Yes | 18 | 21.2 | |
| Smoking during follow up | No | 73 | 85.9 |
| Yes | 12 | 14.1 | |
| PEG | No | 17 | 20.0 |
| Yes | 68 | 80.0 | |
| Px dose to PTV1 | 68.25 Gy | 5 | 5.9 |
| 70 Gy | 80 | 94.1 | |
| Chemotherapy | Concomitant (Platin-based) | 63 | 74.1 |
| Induction + Concomitant | 7 | 8.2 | |
| Cetuximab | 5 | 5.9 | |
| None | 10 | 11.8 |
